Literature DB >> 15373929

Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.

Ulrika Wählby1, Alison H Thomson, Peter A Milligan, Mats O Karlsson.   

Abstract

AIM: If appropriately accounted for in a pharmacokinetic (PK)-pharmacodynamic (PD) model, time-varying covariates can provide additional information to that obtained from time-constant covariates. The aim was to present and apply two models applicable to time-varying covariates that capture such additional information.
METHODS: The first model estimates different covariate-parameter relationships for within- and between-individual variation in covariate values, by splitting the standard covariate model into a baseline covariate (BCOV) effect and a difference from baseline covariate (DCOV) effect. The second model allows the magnitude of the covariate effect to vary between individuals, by inclusion of interindividual variability in the covariate effect. The models were applied to four previously analysed data sets.
RESULTS: The models were applied to 10 covariate-parameter relationships and for three of these the first extended model resulted in a significant improvement of the fit. Even when this model did not improve the fit significantly, it provided useful information because the standard covariate model, which assumes within- and between-patient covariate relationships of the same magnitude, was only supported by the data in four cases. The inclusion of BCOV was not supported in two cases and DCOV was unnecessary in three cases. In one case, significantly different, nonzero, relationships were found for DCOV and BCOV. The second extended model was found to be significant for four of the 10 covariate-parameter relationships.
CONCLUSIONS: On the basis of the examples presented, traditionally made simplifications of covariate-parameter relationships are often inadequate. Extensions to the covariate-parameter relationships that include time-varying covariates have been developed, and their appropriateness and benefits have been described. Copyright 2004 Blackwell Publishing Ltd

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15373929      PMCID: PMC1884602          DOI: 10.1111/j.1365-2125.2004.02170.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection.

Authors:  S Sadray; E N Jonsson; M O Karlsson
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

2.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

3.  A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children.

Authors:  B J Anderson; G A Woollard; N H Holford
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

4.  Assessment of type I error rates for the statistical sub-model in NONMEM.

Authors:  Ulrika Wählby; M René Bouw; E Niclas Jonsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

5.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Authors:  Lena E Friberg; Anja Henningsson; Hugo Maas; Laurent Nguyen; Mats O Karlsson
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

6.  Risk of renal dysfunction in critically ill trauma patients receiving aminoglycosides.

Authors:  G S Jaresko; B A Boucher; E J Dole; E A Tolley; T C Fabian
Journal:  Clin Pharm       Date:  1989-01

7.  Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation.

Authors:  S Fukatsu; I Yano; T Igarashi; T Hashida; K Takayanagi; H Saito; S Uemoto; T Kiuchi; K Tanaka; K Inui; K Tanaka; K Inui
Journal:  Eur J Clin Pharmacol       Date:  2001-09       Impact factor: 2.953

8.  Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.

Authors:  Diane R Mould; Nicholas H G Holford; Jan H M Schellens; Jos H Beijnen; Paul R Hutson; Hilde Rosing; Willem W ten Bokkel Huinink; Eric K Rowinsky; Joan H Schiller; Mark Russo; Graham Ross
Journal:  Clin Pharmacol Ther       Date:  2002-05       Impact factor: 6.875

9.  Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis.

Authors:  Brian J Anderson; Richard A van Lingen; Tom G Hansen; Yuan-Chi Lin; Nicholas H G Holford
Journal:  Anesthesiology       Date:  2002-06       Impact factor: 7.892

10.  Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

Authors:  Thomas J Walsh; Mats O Karlsson; Timothy Driscoll; Adriano G Arguedas; Peter Adamson; Xavier Saez-Llorens; Ajay J Vora; Antonio C Arrieta; Jeffrey Blumer; Irja Lutsar; Peter Milligan; Nolan Wood
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

View more
  29 in total

1.  Preconditioning of Nonlinear Mixed Effects Models for Stabilisation of Variance-Covariance Matrix Computations.

Authors:  Yasunori Aoki; Rikard Nordgren; Andrew C Hooker
Journal:  AAPS J       Date:  2016-02-08       Impact factor: 4.009

Review 2.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

3.  The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.

Authors:  Elisabet Størset; Kristine Hole; Karsten Midtvedt; Stein Bergan; Espen Molden; Anders Åsberg
Journal:  Br J Clin Pharmacol       Date:  2017-02-27       Impact factor: 4.335

4.  Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.

Authors:  Christine E Staatz; Colette Byrne; Alison H Thomson
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

5.  Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery.

Authors:  Iona Macdonald; Christine E Staatz; Roger W Jelliffe; Alison H Thomson
Journal:  Ther Drug Monit       Date:  2008-02       Impact factor: 3.681

6.  Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.

Authors:  Ami F Mohamed; Ilias Karaiskos; Diamantis Plachouras; Matti Karvanen; Konstantinos Pontikis; Britt Jansson; Evangelos Papadomichelakis; Anastasia Antoniadou; Helen Giamarellou; Apostolos Armaganidis; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

7.  Approaches for modeling within subject variability in pharmacometric count data analysis: dynamic inter-occasion variability and stochastic differential equations.

Authors:  Chenhui Deng; Elodie L Plan; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-05-10       Impact factor: 2.745

8.  Model-Based Residual Post-Processing for Residual Model Identification.

Authors:  Moustafa M A Ibrahim; Rikard Nordgren; Maria C Kjellsson; Mats O Karlsson
Journal:  AAPS J       Date:  2018-07-02       Impact factor: 4.009

9.  Concordance between criteria for covariate model building.

Authors:  Stefanie Hennig; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-03-06       Impact factor: 2.745

10.  Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model.

Authors:  Khaled Abduljalil; Masoud Jamei; Amin Rostami-Hodjegan; Trevor N Johnson
Journal:  AAPS J       Date:  2014-04-04       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.